Knee Hyaluronic Acid Injections Market Projected to Grow at 5.2% CAGR Through 2033

The global Knee Hyaluronic Acid Injections Market is projected to grow from USD 2.2 billion in 2023 to USD 3.7 billion by 2033, at a CAGR of 5.2% during the forecast period from 2024 to 2033. This growth is driven by several factors, including the increasing prevalence of osteoarthritis, an aging population, and a preference for non-surgical treatments. Hyaluronic acid injections, also known as viscosupplementation, help improve joint lubrication, reduce pain, and enhance mobility, making them a popular treatment choice for knee osteoarthritis patients.

Recent developments in the market include FDA approvals and ongoing clinical trials for new hyaluronic acid products, which are expected to offer significant opportunities for market players. Companies like Sanofi, Anika Therapeutics, and Zimmer Biomet are actively involved in mergers, acquisitions, and product launches to strengthen their market presence. For instance, Zimmer Biomet recently launched Synvisc-One, a single-injection treatment for knee osteoarthritis, addressing the demand for quicker and more convenient treatment options.

Challenges in the market include the high cost of treatments, which can range from $500 to $1,500 per injection, and regulatory hurdles that can delay the approval and commercialization of new products. Despite these challenges, the market is expected to benefit from technological advancements and increasing awareness about the benefits of hyaluronic acid injections among both patients and healthcare providers.

Overall, the Knee Hyaluronic Acid Injections Market is poised for steady growth, supported by demographic trends, technological innovations, and strategic initiatives by key industry players​.

Key Takeaways

• The market is projected to reach USD 3.7 billion by 2033, growing at a 5.2% CAGR from USD 2.2 billion in 2023.
• The Injection segment is the leading product category, capturing over 41% of the market share.
• Hospitals hold a 56% market share, followed by orthopedic clinics and ambulatory surgical centers, reflecting changing healthcare preferences.
• The osteoarthritis application segment commands over 44% of the market, addressing a prevalent knee joint disorder.
• North America leads with a 37.8% market share (USD 0.83 billion), followed by Europe and Asia-Pacific, with Latin America and the Middle East & Africa showing gradual growth.

Get Sample PDF Report: https://market.us/report/knee-hyaluronic-acid-injections-market/request-sample/

Knee Hyaluronic Acid Injections Market Key Segments

Product

• Single Injection
• Three Injection
• Five Injection

End-Use

• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers
• Others

Application

• Osteoarthritis
• Cartilage Repair
• Other Knee Joint Disorders

Key Regions

• North America (The US, Canada, Mexico)
• Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
• Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
• APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
• Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
• Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)

Buy Directly: https://market.us/purchase-report/?report_id=84542

Key Players Analysis

Sanofi is a prominent player in the knee hyaluronic acid injections market, known for its product Hyalgan. The company focuses on providing effective treatment options for osteoarthritis patients, leveraging its extensive research and development capabilities. Sanofi’s strategy involves expanding its market presence through strategic acquisitions and collaborations. The company also prioritizes the development of next-generation hyaluronic acid formulations to enhance treatment efficacy and patient comfort, addressing the growing demand for minimally invasive osteoarthritis treatments globally​.

Anika Therapeutics, under the DePuy Synthes Inc. umbrella, specializes in orthopedic solutions, including knee hyaluronic acid injections like Orthovisc and Monovisc. Anika’s products are designed to provide long-lasting pain relief and improved joint function. The company’s focus on innovation has led to the development of single and multi-injection regimens that cater to diverse patient needs. Anika also invests heavily in clinical trials and regulatory approvals to maintain its competitive edge in the market​.

Seikagaku Corporation, in collaboration with Zimmer Biomet, is a key player in the knee hyaluronic acid injections sector. The company is known for its JOYCLU 30mg intra-articular injection, which has gained approval in several markets. Seikagaku’s products are recognized for their efficacy in improving joint function and reducing pain in osteoarthritis patients. The company emphasizes strategic partnerships and exclusive distribution agreements to expand its global reach and market share​.

Zimmer Biomet, partnering with Seikagaku Corporation, offers a range of knee hyaluronic acid injections designed to enhance joint lubrication and alleviate pain. The company’s products, such as Gel-One, are tailored to meet the specific needs of osteoarthritis patients. Zimmer Biomet’s approach includes continuous product innovation and expansion into emerging markets, supported by extensive clinical research and robust marketing strategies.

Institut Biochimique SA, now part of Bioventus LLC, focuses on developing and commercializing hyaluronic acid injections for knee osteoarthritis. The company’s leading product, Durolane, is known for its single-injection regimen that offers sustained pain relief. Bioventus emphasizes patient-centric solutions, leveraging advanced technologies to improve treatment outcomes. The company’s strategic initiatives include expanding its product portfolio and enhancing its global distribution network to cater to the rising demand for effective osteoarthritis treatments​​.

Knee Hyaluronic Acid Injections Market Key Players:

• Sanofi
• Anika Therapeutics Inc. (DePuy Synthes Inc.)
• Seikagaku Corporation
• Zimmer Biomet
• Institut Biochimique SA (Bioventus LLC)
• Fidia Farmaceutici S.p.A
• Meiji Seika Pharma Co. Ltd. (OrthogenRx)
• Ferring B.V.
• Viatrus Inc.
• Hanmi Pharm Co. Ltd. (Teva Pharmaceuticals Industries Ltd.)
• Chugai Pharmaceuticals Co. Ltd.
• Haohai Biological Technology
• Hunan Jingfeng Pharmaceutical Co. Ltd.

Knee Hyaluronic Acid Injections Market Report Scope >> Market Value (2023): USD 2.2 Billion || Forecast Revenue (2033): USD 3.7 Billion || CAGR (2024-2033): 5.2% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.